Article
Chemistry, Multidisciplinary
Qian Li, Zhipeng Zhao, Xiaohan Qin, Mengzhu Zhang, Qian Du, Zhonghao Li, Yuxia Luan
Summary: A PD-L1 checkpoint-regulatable immune niche has been created by an injectable hydrogel, reprogramming PD-L1 of both tumor cells and circulating exosomes, offering an innovative approach to cancer immunotherapy.
ADVANCED FUNCTIONAL MATERIALS
(2021)
Article
Biochemistry & Molecular Biology
Zaigang Zhou, Yu Liu, Xin Jiang, Chunjuan Zheng, Wenjuan Luo, Xinli Xiang, Xiaoliang Qi, Jianliang Shen
Summary: Recently, it was discovered that the highly expressed PD-L1 in tumor cells significantly impairs the DNA damage induced by Cis-Pt chemotherapy. Additionally, severe side effects of Cis-Pt, such as enhanced drug efflux caused by MDR-1 and increased tumor metastasis, limit its efficacy. However, a new finding shows that Ch-Met has selective mitochondria accumulation capacity, disrupting mitochondrial function and effectively inhibiting upregulated PD-L1 expression, DNA damage repair, drug efflux, and tumor metastasis. This suggests that Ch-Met can enhance the chemotherapy efficacy of Cis-Pt.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Immunology
Urban Svajger, Natasa Tesic, Primoz Rozman
Summary: This study demonstrates the importance of IFN-gamma in inducing PD-L1 expression on DCs, leading to an immunosuppressive effect and the induction of Tregs. The PD-L1high DCs treated with IFN-gamma show increased regulatory function, inhibiting CD4(+) T cell proliferation and promoting the generation of Tregs.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Chin-Shan Kuo, Cheng-Yu Yang, Chih-Kung Lin, Gu-Jiun Lin, Huey-Kang Sytwu, Yuan-Wu Chen
Summary: The study found significant overexpression of PD-L1 in oral squamous cell carcinoma tissues, and that IFN-gamma can drive PD-L1 expression in OSCC cells. Triptolide (TPL) can suppress oral cancer growth and downregulate PD-L1 expression in oral cancer cells in vitro.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Immunology
Lin Zhang, Bo Hao, Zhihua Geng, Qing Geng
Summary: Toripalimab, a selective anti-PD-1 monoclonal antibody, has shown anti-tumor effects in melanoma, nasopharyngeal carcinoma, and urothelial carcinoma, and could be a valuable choice for future tumor treatment decision-making.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Yu-Chi Chen, Xin-Ling He, Lu Qi, Wei Shi, Luo-Wei Yuan, Mu-Yang Huang, Yu-Lian Xu, Xiuping Chen, Lei Gu, Le-Le Zhang, Jin-Jian Lu
Summary: In this study, it was found that myricetin (MY) can inhibit the expression of PD-L1 and IDO1 induced by interferon-gamma (IFN-gamma) in lung cancer cells and restore the function of T cells. This discovery highlights the potential role of MY in tumor immunotherapy.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Plant Sciences
Zi-Xuan Gao, Zhan-Sheng Zhang, Jia Qin, Ming -Zhu Zhang, Jin-Lan Cao, Ying-Ying Li, Meng-Qing Wang, Dong Fang, Song-Qiang Xie
Summary: This study evaluated the antitumor effects of aucubin on hepatocellular carcinoma (HCC) and investigated its synergistic effects with cisplatin. The results showed that aucubin inhibited tumor growth and suppressed PD-L1 expression through the Akt/beta-catenin signaling pathway. Aucubin also enhanced the antitumor activity of cisplatin by blocking PD-L1 expression.
Review
Immunology
Rilan Bai, Jiuwei Cui
Summary: Antibodies targeting PD-1/PD-L1 have been considered breakthrough therapies for cancer. In addition to T cell-driven immune responses, blocking PD-1/PD-L1 may also enhance the function and activity of NK cells, which are often overlooked in previous studies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Yu Liu, Zaigang Zhou, Jiting Hou, Wei Xiong, Heejeong Kim, Jiashe Chen, Chunjuan Zheng, Xin Jiang, Juyoung Yoon, Jianliang Shen
Summary: In this study, a new PD-L1 regulation strategy was developed by selectively down-regulating PD-L1 expression in tumors using mitochondria-targeted IR-LND@Alb nanoparticles. The anti-tumor efficacy of this strategy was found to be superior to conventional anti-PD-L1 monoclonal antibodies. Interestingly, IR-LND also showed potential as a novel photodynamic therapy (PDT) drug with self-oxygen and self-PD-L1 regulation capability.
ADVANCED MATERIALS
(2022)
Article
Oncology
Daniel R. Principe, Patrick W. Underwood, Sandeep Kumar, Kaytlin E. Timbers, Regina M. Koch, Jose G. Trevino, Hidayatullah G. Munshi, Ajay Rana
Summary: This study found that loss of SMAD4 is associated with decreased tumor immunity and reduced T-cell infiltrate in pancreatic ductal adenocarcinoma. SMAD4 loss is also correlated with reduced expression of chemokines involved in T-cell recruitment. Additionally, SMAD4 indirectly promotes PD-L1 expression by enhancing T-cell infiltration and IFN gamma biosynthesis. These findings suggest that SMAD4 status may serve as a predictive biomarker for cancer immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Liza C. Villaruz, George R. Blumenschein Jr, Gregory A. Otterson, Ticiana A. Leal
Summary: The development of PD-1/PD-L1 immune checkpoint inhibitors has revolutionized the treatment of advanced and/or metastatic NSCLC. However, many patients do not respond or only have a temporary benefit from these agents. Resistance mechanisms, such as upregulation of immune checkpoints and immunosuppressive tumor microenvironment, need to be overcome to improve patient outcomes. This review discusses novel therapeutic strategies to enhance responses to PD-(L)1 inhibitors and counter resistance in NSCLC, and summarizes the latest clinical evidence.
Review
Oncology
Yuanfeng Zhang, Juanjuan Wu, Chaobin Zhao, Shuyuan Zhang, Jianbo Zhu
Summary: Programmed death-1 (PD-1) is a protein on immune cells that interacts with programmed death-ligand 1 (PD-L1), expressed on various cellular locations. This interaction may lead to immune evasion in cancer patients. PD-L1 plays a crucial role in cancer diagnosis, therapeutic effectiveness, and patient prognosis, and PD-L1 inhibitors are essential in tumor immunotherapy. Recent advancements in PD-L1 detection methods have been made, and this review summarizes the progress in tumor PD-L1 detection technology and its clinical applications.
Article
Immunology
Tomohiro Ogawa, Keiko Kan-o, Ayaka Shiota, Akitaka Fujita, Yumiko Ishii, Satoru Fukuyama, Koichiro Matsumoto
Summary: This study found that during viral infections, antiviral interferons can induce the expression of PD-L1 and PD-L2 in bronchial epithelial cells. By inhibiting the PI3K delta signaling pathway, the expression of these two immune checkpoint molecules can be differentially regulated in bronchial epithelial cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yutaro Kondo, Susumu Suzuki, Shoya Ono, Mitsuo Goto, Satoru Miyabe, Tetsuya Ogawa, Hiromi Tsuchida, Hideaki Ito, Taishi Takahara, Akira Satou, Toyonori Tsuzuki, Kazuhiro Yoshikawa, Ryuzo Ueda, Toru Nagao
Summary: The expression of PD-L1 is regulated by complex mechanisms. This study focused on the mechanisms of PD-L1 expression in OSCCs and found that EGF and IFN-gamma upregulate PD-L1 through different signaling pathways. Moreover, the phosphorylation pattern of related molecules in PD-L1-positive cells varied among different cases. These findings suggest that choosing the appropriate combination drugs for PD-1 blockade cancer treatment should consider the tissue environment and molecular alterations affecting PD-L1 expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Chao Cheng, Lingdun Zhuge, Xin Xiao, Siyuan Luan, Yong Yuan
Summary: As the predominant treatment option for advanced esophageal cancer, PD-1 and PD-L1 inhibitors provide new hope to clinical practice. However, some patients do not respond to this therapy and most initially sensitive patients eventually develop resistance. Therefore, it is critical to understand the mechanisms of resistance and explore efficient strategies to overcome it, in order to expand the benefit of immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)